A section of the community wants the caste name to be officially recorded as “Bhumihar-Brahmin” before the 2027 national caste census.

Myqorzo (aficamten) is a new therapy for oHCM, improving functional capacity and symptoms, with an annual cost of $108,400. The Myqorzo & You program provides personalized support, including insurance ...

“The last thing a presbyopic patient wants is to abandon their reading glasses and walk around with cosmetically red eyes,” ...

New research proves the benefits of strength training for running economy – so here’s how to make the most of your ...

The burden of presbyopia and reading glasses drives patients to look for solutions.“There is a clear and growing patient ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Credo Technology Group Holding Ltd's outlook is bearish as optical interconnects threaten AEC demand. Click for an updated ...

Tenpoint Therapeutics’ Yuvezzi gets US FDA nod; the first and only combo eye drop approved to treat presbyopia: London Saturday, January 31, 2026, 14:00 Hrs [IST] Tenpoint Thera ...

Novo Nordisk is fighting back with CagriSema, a powerful combination therapy that demonstrated 22.7% weight loss in its own Phase 3 trials. While this result is superior to the current market leader, ...

Pfizer Balances COVID Drag With Pipeline Momentum in Latest Earnings Call The overall tone of Pfizer Inc.’s latest earnings call was cautiously optimistic, with management emphasizing underlying ...